Drug intelligence / Profile preview

PMD-026 + fulvestrant

Development stage: Unknown
Lead developer: Phoenix Molecular Designs
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

PMD-026 + fulvestrant is a combination therapy consisting of PMD-026, a first-in-class oral pan-RSK inhibitor, and fulvestrant, a selective estrogen receptor degrader. PMD-026 inhibits the serine/threonine kinase p90 ribosomal S6 kinase (p90RSK; RSK) subtypes 1-4, with high selectivity for RSK subtype 2. This combination is being developed by Phoenix Molecular Designs for the treatment of locally advanced or metastatic HR+/HER2-/RSK2-high breast cancer in patients who have progressed after CDK4/6 inhibitor treatment.

Targets

RPS6KA3 (RSK2)ER (Estrogen receptor)RPS6KA1 (Ribosomal S6 kinase Alpha-1)

Beyond the preview

Go deeper on PMD-026 + fulvestrant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMD-026 + fulvestrant.

Explore the full profile